Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

5.6K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.8K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.8K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

10.3K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
10.3K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

565
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
565
Patient-centered Care01:13

Patient-centered Care

3.2K
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide study of gene-by-sex interactions identifies risks for cleft palate.

medRxiv : the preprint server for health sciences·2024
Same author

Solving the Puzzle of Preterm Birth.

Clinics in perinatology·2024
Same author

Ambient Environment and the Epidemiology of Preterm Birth.

Clinics in perinatology·2024
Same author

Vascular health years after a hypertensive disorder of pregnancy: The EPOCH study.

American heart journal·2024
Same author

Corrigendum: Advances and potential of omics studies for understanding the development of food allergy.

Frontiers in allergy·2024
Same author

A search for factors associated with reduced carbohydrate intake and NTD risk in two population-based studies.

Birth defects research·2024
Same journal

Corrigendum for: Levels of folate receptor autoantibodies in maternal and cord blood and risk of neural tube defects in a Chinese population, 106:685-695 (10.1002/bdra.23517).

Birth defects research. Part A, Clinical and molecular teratology·2016
Same journal

Response to letter to the editor by Wise.

Birth defects research. Part A, Clinical and molecular teratology·2016
Same journal

Letter to the editor: Comments on venlafaxine paper by Laurent et al.

Birth defects research. Part A, Clinical and molecular teratology·2016
Same journal

Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011.

Birth defects research. Part A, Clinical and molecular teratology·2016
Same journal

Evaluation of the Western Australian Register of Developmental Anomalies: Thirty-five years of surveillance.

Birth defects research. Part A, Clinical and molecular teratology·2016
Same journal

A quality assessment of reporting sources for microcephaly in Utah, 2003 to 2013.

Birth defects research. Part A, Clinical and molecular teratology·2016
See all related articles

Related Experiment Video

Updated: Mar 11, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

Response to Dr. Kirby

Gary M Shaw, Wei Yang, Suzan L Carmichael

    Birth Defects Research. Part A, Clinical and Molecular Teratology
    |December 2, 2016
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes
    07:58

    qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes

    Published on: March 6, 2019

    9.1K
    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
    09:54

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

    Published on: May 22, 2020

    4.0K

    Related Experiment Videos

    Last Updated: Mar 11, 2026

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
    07:42

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

    Published on: September 19, 2018

    8.4K
    qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes
    07:58

    qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes

    Published on: March 6, 2019

    9.1K
    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
    09:54

    Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

    Published on: May 22, 2020

    4.0K